Methylene Blue and Semax Interaction: Monitor | Peptide Database

First-line treatment for elevated LDL cholesterol and mixed dyslipidemia. Rosuvastatin 10-20 mg achieves LDL reductions of 45-55%, outperforming equivalent doses of other statins. Particularly appropriate when aggressive LDL lowering is required or when patients have not reached lipid targets on less potent statins. Widely used off-label to manage lipid disturbances caused by anabolic steroid cycles, especially oral AAS (oxandrolone, stanozolol, methandrostenolone) that severely impact lipid profiles. Typical on-cycle doses of 5-10 mg daily can meaningfully reduce LDL elevation, though HDL suppression caused by androgens is only partially mitigated. Most effective when started before or at the beginning of a cycle rather than reactively. Proven to reduce major cardiovascular events including myocardial infarction, stroke, and cardiovascular death. The JUPITER trial showed a 44% reduction in major cardiovascular events in apparently healthy individuals with elevated hsCRP. Particularly relevant for long-term AAS users who accumulate cardiovascular risk over time. Indicated for cardiovascular risk reduction in individuals without established cardiovascular disease but with risk factors such as dyslipidemia, family history, or elevated inflammatory markers. The JUPITER trial established benefit even in patients with LDL below 130 mg/dL if hsCRP was elevated above 2 mg/L. The METEOR trial demonstrated that rosuvastatin 40 mg significantly slowed progression of carotid intima-media thickness compared to placebo in low-risk patients with subclinical atherosclerosis. Suggests benefit in slowing vascular damage that may accumulate in chronic AAS users.

Restores endogenous testosterone production in men with secondary hypogonadism by increasing LH and FSH through hypothalamic estrogen receptor antagonism. Phase III trials demonstrated significant testosterone normalization. Provides a non-suppressive alternative to exogenous testosterone for men seeking to raise testosterone levels while maintaining natural HPTA function and fertility. Can serve as a standalone alternative to testosterone replacement therapy in appropriate candidates, particularly younger men or those concerned about fertility preservation. Accelerates recovery of the hypothalamic-pituitary-testicular axis after suppression from anabolic steroids or exogenous testosterone by rapidly increasing LH and FSH output. Helps restore natural testosterone production to baseline levels faster than unassisted recovery, reducing the hypogonadal window after cycle cessation. FSH elevation driven by enclomiphene supports Sertoli cell function and spermatogenesis, making it useful for men with oligospermia associated with secondary hypogonadism. Can be used as a bridge off TRT for men who wish to conceive, maintaining testosterone levels while restoring spermatogenesis.